DUBLIN--(EON: Enhanced Online News)--Malin Corporation plc. ("Malin"), an Irish based and globally operating life sciences company, today announced that it has acquired a 32% shareholding of Artizan Biosciences, Inc. (“Artizan”). Malin invested in a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership.
“Artizan’s strong foundational science underpins a platform that has potential therapeutic applicability across a number of diseases. Artizan’s proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders.”
Artizan is a newly created biotechnology company headquartered in Durham, NC, with labs in New Haven, CT, that was founded to address diseases involving the human intestinal microbiota. This is an area of rapidly emerging, leading human health life science and, with additional progress, offers a broad possibility of potential therapeutic applications.
Artizan was spun out of Yale University and established as a standalone business in 2016. Highly innovative and far reaching research from Prof. Richard Flavell’s, PhD, FRS, laboratory at Yale has been the basis for the establishment of this undertaking. In sum, the research to date has demonstrated that the specific composition of the intestinal microbiota varies substantially between individuals. This observation, in turn, creates a pathway to key determinants of individualised susceptibility to a broad array of diseases.
In collaboration with Prof. Noah Palm, PhD, at Yale, Artizan has developed a capability of distinguishing certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for any number of digestive disorders as well as other diseases including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system (CNS) diseases.
Artizan’s Scientific Founders include Prof. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD, from Yale University. Artizan is led by CEO, Mr. James Rosen. Mr. Rosen brings over 25 years’ experience in the healthcare industry including a dozen years in venture capital at Intersouth Partners and most recently he led the venture capital investment practice for The Bill & Melinda Gates Foundation.
Adrian Howd, PhD, Chief Investment Officer of Malin, said: “Artizan’s strong foundational science underpins a platform that has potential therapeutic applicability across a number of diseases. Artizan’s proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders."
Prof. Richard Flavell, Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute, one of the Founders of Artizan, added: "Our goal to build Artizan into a sustainable, highly innovative and potentially disruptive biotechnology company that, with tangible clinical progress, will offer new therapeutic options for patients suffering from a wide variety of diseases. We intend to be a leader in the microbiota-driven inflammatory diseases space, which is both broad and far reaching.”
About Malin Corporation Plc.
Malin is an Irish incorporated public limited company. Its purpose is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-IPO, pre-trade sale operating businesses in dynamic and fast growing segments of the life sciences industry. Through its operational involvement, Malin works with its investee companies to enable them to reach the full potential of their value proposition and to achieve commercial success. For more information visit www.malinplc.com
About Artizan Biosciences, Inc.
Artizan Biosciences is a biotechnology company based in Durham, NC, with labs in New Haven, CT, and is focused on drug discovery and development for diseases involving the human intestinal microbiota. Artizan has developed a proprietary platform for distinguishing pathogenic bacteria from the remainder of the intestinal microbiota and has a therapeutic strategy to target these bacteria as treatment for inflammatory bowel diseases (IBD). Potentially, this strategy could be implemented for a variety of other microbiota-driven conditions such as obesity, autoimmune disease and a variety of skin, lung and CNS diseases.
About Inflammatory Bowel Disease
IBD is a chronic, relapsing inflammatory disorder of the gastrointestinal tract that is difficult to manage and has no current cure. The disease affects approximately 1.6 million people in the United States alone, is the cause of nearly 300,000 hospitalisations per year.